Prevacid and Erbitux drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Prevacid (lansoprazole) and Erbitux (cetuximab). Common drug interactions include acne among females and dyspnoea among males.

The phase IV clinical study analyzes what interactions people have when they take Prevacid and Erbitux. It is created by eHealthMe based on reports of 41 people who take the same drugs from the FDA, and is updated regularly.

What is Prevacid?

Prevacid has active ingredients of lansoprazole. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 130,714 Prevacid users. Check the latest studies of Prevacid.

What is Erbitux?

Erbitux has active ingredients of cetuximab. It is often used in cancer. eHealthMe is studying from 19,276 Erbitux users. Check the latest studies of Erbitux.

On Jul, 17, 2026

41 people who take Prevacid and Erbitux together, and have interactions are studied.

What are the common drug interactions of Prevacid and Erbitux, by gender? *:

female:

Acne (skin problems that cause pimples)
Anorexia (eating disorder characterized by immoderate food restriction and irrational fear of gaining weight)
Blood magnesium decreased
Blood pressure decreased
Chills (felling of cold)
Colon cancer metastatic (cancer of colon spreads to other part of body)
Dehydration (dryness resulting from the removal of water)
Diarrhoea
Dysphagia (a condition in which swallowing is difficult or painful)
Dyspnoea (difficult or laboured respiration)

male:

Dyspnoea (difficult or laboured respiration)
Nausea (feeling of having an urge to vomit)
Cerebral infarction (less blood supply to brain resulting tissue damage)
Electrocardiogram qt corrected interval prolonged
Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)
Hemiparesis (weakness on one side of the body)
Loss of consciousness
Pyrexia (fever)
Thrombocytopenia (decrease of platelets in blood)
Vomiting

What are the common drug interactions of Prevacid and Erbitux, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Hypoxia (low oxygen in tissues)
Interstitial lung disease
Pulmonary embolism (blockage of the main artery of the lung)

50-59:

Nausea (feeling of having an urge to vomit)
Pyrexia (fever)
Chills (felling of cold)
Dermatitis acneiform (dermatoses including acne vulgaris, rosacea, folliculitis, and perioral dermatitis)
Dyspnoea (difficult or laboured respiration)
Hypotension (abnormally low blood pressure)
Mucosal inflammation (infection of mucous membrane)
Urinary tract infection
Vomiting
Infusion related reaction

60+:

Dyspnoea (difficult or laboured respiration)
Cardio-respiratory arrest (sudden dysfunction of heart and lungs)
Vomiting
Chills (felling of cold)
Tachycardia (a heart rate that exceeds the range of 100 beats/min)
Abdominal pain
Abdominal pain upper
Anal discomfort
Anaphylactic reaction (serious allergic reaction)
Blister (small pocket of fluid within the upper layers of the skin caused by forceful rubbing (friction), burning, freezing, chemical exposure)

What are the existing conditions these people have? *

Colon Cancer: 8 people, 19.51%
Neoplasm Malignant (cancer tumour): 7 people, 17.07%
Oral Cancer (mouth cancer): 6 people, 14.63%
Pain: 3 people, 7.32%
Nausea (feeling of having an urge to vomit): 3 people, 7.32%
Lung Cancer - Non-Small Cell (lung cancer): 3 people, 7.32%

* Approximation only. Some reports may have incomplete information.

Do you take Prevacid and Erbitux?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously